<DOC>
	<DOCNO>NCT02107378</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/OvCa add chemotherapy may result prolongation Overall Survival ( OS ) .</brief_summary>
	<brief_title>Efficacy DCVAC/OvCa Plus Standard Care Relapsed Platinum Resistant Epithelial Ovarian Carcinoma</brief_title>
	<detailed_description>The purpose study determine whether DCVAC/OvCa add Standard Care chemotherapy may result prolongation Overall Survival ( OS ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Females 18 year old Histologically confirm International Federation Gynecology Obstetrics ( FIGO ) Stage III IV epithelial ovarian , primary peritoneal , fallopian tube carcinoma ( serous , endometrioid mucinous ) , undergone initial surgery interval debulking surgery reach complete remission 6 month first line platinum base chemotherapy , one follow reason Patients platinumrefractory ( response ) Complete remission reach ( partial responder ) Relapse within ≤6 month remission ( Platinumresistant ) Platinumbased chemotherapy failure confirm computerized tomography ( CT ) /magnetic resonance imaging ( MRI ) scan ( Platinumresistant ) find describe 'did reach complete clinical remission ' ( Platinumrefractory Platinumpartial response ) Patients must least one measureable target lesion define Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 criterion Eastern Cooperative Oncology Group ( ECOG ) Performance status 0−2 FIGO I , II epithelial ovarian cancer FIGO III , IV clear cell epithelial ovarian cancer Nonepithelial ovarian cancer Borderline tumor ( tumor low malignant potential ) Prior current systemic anticancer therapy ovarian cancer [ example chemotherapy , monoclonal antibody therapy , tyrosine kinase inhibitor therapy , vascular endothelial growth factor ( VEGF ) therapy hormonal therapy ] except first line Platinumbased chemotherapy ( without bevacizumab ) Previous radiotherapy abdomen pelvis Malignancy epithelial ovarian cancer , except clinical remission ( CR ) minimum 3 year , except carcinoma insitu cervix nonmelanoma skin carcinoma Clinically significant cardiovascular disease Active autoimmune disease require treatment History severe form primary immune deficiency Systemic immunosuppressive therapy reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Serous</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Platinum resistant ( pt )</keyword>
	<keyword>Ovarian Cancer ( OvCa )</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>